BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Grant number: 1157717 | Funding period: 2019 - 2022

Active

Abstract

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to suboptimal MS management and accumulation of preventable disability. We will use MSBase, the largest international MS cohort, and several international cohorts, to build an algorithm that will enable physicians to identify the best treatment for individual patients with MS at any given time.

Related publications (4)

Scholarly works icon

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Eva Kubala Havrdova, Raed Alroughani, Guillermo Izquierdo, Serkan Ozakbas, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, Francois Grand'Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz

2021-09-18

INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting mult..

Scholarly works icon

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

Johanna B Andersen, Sifat Sharmin, Mathilde Lefort, Nils Koch-Henriksen, Finn Sellebjerg, Per Soelberg Sorensen, Claudia C Hilt Christensen, Peter Rasmussen, Michael B Jensen, Jette L Frederiksen, Stephan Bramow, Henrik K Mathiesen, Karen Schreiber, Dana Horakova, Eva K Havrdova, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Francesco Patti

2021-08-01

BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsi..

Scholarly works icon

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi

2020-09-01

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies re..

Scholarly works icon

Early clinical markers of aggressive multiple sclerosis

Charles B Malpas, Ali Manouchehrinia, Sifat Sharmin, Izanne Roos, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Francois Grand'Maison, Serkan Ozakbas, Vincent Van Pesch

2020-05-01

Patients with the ‘aggressive’ form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Di..